靶向腫瘤學 SCIE

期刊簡介預計審稿時間： 12周，或約稿

Targeted Oncology addresses physicians and scientists committed to oncology and cancer research by providing a programme of articles on molecularly targeted pharmacotherapy in oncology. The journal includes:

Original Research Articles on all aspects of molecularly targeted agents for the treatment of cancer, including immune checkpoint inhibitors and related approaches.

Comprehensive narrative Review Articles and shorter Leading Articles discussing relevant clinically established as well as emerging agents and pathways.

Current Opinion articles that place interesting areas in perspective.

Therapy in Practice articles that provide a guide to the optimum management of a condition and highlight practical, clinically relevant considerations and recommendations.

Systematic Reviews that use explicit, systematic methods as outlined by the PRISMA statement.

Adis Drug Reviews of the properties and place in therapy of both newer and established targeted drugs in oncology.

《靶向腫瘤學》通過提供一系列關于腫瘤學分子靶向藥物治療的文章，為致力于腫瘤學和癌癥研究的醫生和科學家提供服務。該期刊包括：

關于癌癥治療的分子靶向藥物各個方面的原創研究文章，包括免疫檢查點抑制劑和相關方法。

全面的敘述性評論文章和較短的領先文章，討論相關的臨床已建立的以及新興的藥物和途徑。

當前觀點文章，從角度看待有趣的領域。

實踐中的治療文章，為病情的最佳管理提供指南，并強調實用的、臨床相關的考慮因素和建議。

使用 PRISMA 聲明概述的明確、系統方法的系統評價。

Adis 藥物評論，介紹腫瘤學中較新和已建立的靶向藥物的特性和治療地位。

《Targeted Oncology》(靶向腫瘤學)編輯部通訊方式為SPRINGER, VAN GODEWIJCKSTRAAT 30, DORDRECHT, NETHERLANDS, 3311 GZ。如果您需要協助投稿或潤稿服務，您可以咨詢我們的客服老師。我們專注于期刊咨詢服務十年，熟悉發表政策，可為您提供一對一投稿指導，避免您在投稿時頻繁碰壁，節省您的寶貴時間，有效提升發表機率，確保SCI檢索（檢索不了全額退款）。我們視信譽為生命，多方面確保文章安全保密，在任何情況下都不會泄露您的個人信息或稿件內容。